Incoming FogPharma CEO Mathai Mammen discusses the next frontier of cell-penetrating peptides, as the company advances a first candidate into the clinic to take on beta-catenin.
机构:
Stockholm Univ, Dept Neurochem, S-10691 Stockholm, SwedenStockholm Univ, Dept Neurochem, S-10691 Stockholm, Sweden
Hansen, Mats
论文数: 引用数:
h-index:
机构:
Kilk, Kalle
Langel, Ulo
论文数: 0引用数: 0
h-index: 0
机构:
Stockholm Univ, Dept Neurochem, S-10691 Stockholm, Sweden
Univ Tartu, Inst Technol, EE-50411 Tartu, EstoniaStockholm Univ, Dept Neurochem, S-10691 Stockholm, Sweden